Characterization of the Plasma Proteome Following Left Ventricular Assist Device Implantation

Completed

Conditions studied: Ventricular Dysfunction, Left

In brief

The purpose of this study is to characterize changes in the plasma proteome over time following left ventricular assist device (LVAD) implantation.

Key facts

Study ID

NCT02428894

Run by

University of Colorado, Denver

People needed

20

Starts

2014-10-01

Expected to finish

2017-01-01

Last updated by the study team

2017-07-17

Who can join

Age: 21 and older, up to 90. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Planned HeartMate II LVAD implantation
• Planned warfarin (goal INR, 2.0-3.0) and low-dose aspirin therapy post-LVAD placement

You may not qualify if…

• Prior history of mechanical circulatory support;
• Body weight < 110 lbs;
• Pre-existing hemolytic, bleeding, or immunologic disorders prior to LVAD implantation;
• Severe aortic stenosis;
• Renal failure requiring dialysis;
• Hepatic dysfunction resulting in severe coagulopathies;
• Recent serious infection;
• Current need for prolonged ventilatory support;
• Prior organ transplantation;
• Blood transfusion within 14 days of the first planned study blood draw;
• Concomitant immunosuppressant or chemotherapeutic agents;
• Pregnant women;
• Decisionally challenged or prisoners;
• Unwilling to provide written informed consent

Where it is running

• University of Colorado Anschutz Medical Campus — Aurora, Colorado, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.